Breast conservation therapy in patients with stage T1-T2 breast cancer: Current challenges and opportunities

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 5, 2010, Pages 500-510

  Perez, Carlos A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Breast conservation therapy; Controversies in breast cancer

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; FOLLOW UP; HUMAN; PARTIAL MASTECTOMY; PROGNOSIS; RACE DIFFERENCE; SOCIOECONOMICS; TREATMENT FAILURE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AFRICAN AMERICAN; BREAST TUMOR; CAUCASIAN; ETHNOLOGY; FEMALE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SEGMENTAL MASTECTOMY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ADULT; AFRICAN AMERICANS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; MISSOURI; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78049419972     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d31f15     Document Type: Article

References (80)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin. 2009;59:225-249.
2. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res. 2007; 9:R28.
3. Keynes G. Conservative treatment of cancer of the breast. Br Med J. 1937;3:643-647.
4. Mustakallio S. Uber die moglichkeiten der rontgentherapie bei der behandlung des brustkrebses. Acta Radiol. 1945;26:503-522.
5. Mustakallio S. Conservative treatment of breast carcinoma: review of 25 years follow-up. Clin Radiol. 1972;23:110-116.
6. Perez CA, Taylor ME, Bradley JBreast: T1-T2 tumors. In: Perez CA, Brady LW, Halperin EC, et al, eds. Principles and Practice of Radiation Oncology. 4th ed. Baltimore, MD: Lippincott Williams and Wilkins; 2004:1331
7. Perez CA. Conservation therapy in T1-T2 breast cancer: past, current issues and future challenges and opportunities. Cancer J. 2003;9:442-453.
8. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer: College of American Pathologist Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
9. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958;8:699-713.
10. Cox DR. Regression models and life tables. J R Stat Soc Series B. 1972;34: 187-220.
11. Dixon WJ. BMDP Statistical Software. Los Angeles, CA: University of California Press; 1982.
12. Dixon WJ. News for 1987 Release of BMDP Statistical Software. Los Angeles, CA: University of California Press; 1986.
13. O'Malley CD, Le GM, Glaser SL, et al. Socioeconomic status and breast carcinoma survival in four racial/ethnic groups: a population-based study. Cancer. 2003;97:1303-1311.
14. Newman LA. African American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African American and 40,000 white American patients with carcinoma of the breast. Cancer. 2002;94:2844-2854.
15. Ansell D, Whitman S, Lipton R, et al. Race, income and survival from breast cancer at two public hospitals. Cancer. 1993;72:2974-2978.
16. Moran MS, Harris LN, Haffty BG. Differences between African American and Caucasian patients treated with breast conservative surgery and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys. 2007;69(suppl 3): S4.Abstract 8.
17. Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcome of African American versus white breast cancer patients: retrospective analysis of SWOG studies S 8814/8897. J Clin Oncol. 2009:27: 2157-2162.
18. Bradley CJ, Given CW, Robert C. Race, socioeconomic status and breast cancer treatment and survival. J Natl Cancer Inst. 2002;94:490-496.
19. Yood MU, Johnson CC, Blount A, et al. Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst. 1999;91:1487-1491.
20. Mandelblatt JS, Kerner JF, Hadley J, et al. Variations in breast carcinoma treatment in older medical beneficiaries: is it black or white. Cancer. 2002; 95:1401-1414.
21. Freedman RA, He Y, Winer EP, et al. Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol. 2009;27: 713-719.
22. Lund MJ, Brawley OP, Ward KC, et al. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat. 2008;109:545-557.
23. Schroen AT, Brenin DR, Kelly MD, et al. Impact of distance to radiation therapy on mastectomy use in early-stage breast cancer patients. J Clin Oncol. 2005;23:7074-7080.
24. Goldstein NS, Kestin L, Vicini F. Factors associated with ipsilateral breast failures and distant metastasis in patients with invasive breast carcinoma treated with breast conservation therapy: a clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol. 2003;120:500-527.
25. DiBiase SJ, Komarnicky LT, Heron DE, et al. Influence of radiation dose on positive surgical margins in women undergoing breast conservation therapy. Int J Radiat Oncol Biol Phys. 2002;53:680-686.
26. Hardy K, Fradette K, Gheorghe R, et al. The impact of margin status on local recurrence following breast conserving therapy for invasive carcinoma in Manitoba. Surg Oncol. 2008;98:399-402.
27. Leong C, Boyages J, Jayasinghe UW, et al. Effect of margins on ipsilateral breast tumor recurrence after breast conservation therapy for lymph node negative breast carcinoma. Cancer. 2004;100:1823-1832. (Pubitemid 38529559)
28. Okumura S, Michihide M, Chikako Y, et al. Feasibility of breast conserving therapy for macroscopically multiple ipsilateral breast cancer. Int J Radiat Oncol Biol Phys. 2004;59:146-151.
29. Harris JR, Connolly JL, Schnitt SJ, et al. The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy. Ann Surg. 1985;201:164-169.
30. Antonini N, Heather J, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol. 2007;82:265-271.
31. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation sdose on local control and survival in breast-conserving therapy of early breast cancer: 10 year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259-3265.
32. Vicini F, Baglan K, Kestin L, et al. The emerging role of brachythaerapy in the management of patients with breast cancer. Semin Radiat Oncol. 2002; 12:31-39.
33. Poortmans PM, Collette L, Horiot JC, et al. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early breast cancer after a microscopically incomplete resection. Radiother Oncol. 2009;90:80-85.
34. Recht A, Edge SB, Solin LJ, et al. Post-mastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1539-1569.
35. Overgaard M, Hansen PS, Overgaard J, et al. Randomized trial evaluating postoperative radiotherapy in high risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N Engl J Med. 1997;337:949-955.
36. Ragaz J, Olovotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005;97:116-126. (Pubitemid 40277091)
37. Overgaard M, Jensen MB, Overgaard J, et al. Randomized trial evaluating postoperative radiotherapy in high risk postmenopausal breast cancer patients given adjuvant tamoxifen: results from the DBCG 82c trial. Lancet. 1999; 353:1641-1648.
38. Truong PT, Jones SO, Kader HA, et al. Patients with T1 to T2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node negative patients after breast-conserving surgery and wholebreast radiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:357-364.
39. Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol. 2009;27:4082-4088.
40. Tuttle TM, Habermann EB, Grund EH, et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol. 2007;33:5203-5209.
41. Solin LJ, Orel SG, Hwang WT, et al. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast cancer or ductal carcinoma in situ. J Clin Oncol. 2008;26:386-391.
42. Hwang N, Schiller DE, Crystal P, et al. Magnetic resonance imaging in the planning of initial lumpectomy for invasive breast carcinoma: ipsilateral tumor recurrence after breast-conservation therapy. Ann Surg Oncol. 2009; 16:3000-3009.
43. Van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536.
44. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005;23:7350-7360.
45. Paik S, Shak S, Tang G. A multigene assay to predict recurrence of tamoxifen-treated node negative breast cancer. N Engl J Med. 2004;351: 2817-2826.
46. Butta A, MacLennan K, Flanders KC, et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res. 1992;52:4261-4264.
47. Azria D, Rosenstein BS, Ozsahim M. Radiation-induced side-effects with or without systemic therapies: prime time for prediction of individual radiosensitivity. Int J Radiat Oncol Biol Phys. 2008;71:1293-1294.
48. Azria D, Larbouret C, Cunat S, et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res. 2005;7:R156-R163.
49. Clarke M, Collins R, Darby S, et al. (EBCTCG) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087-2106.
50. Hooning MJ, Aleman BM, van Rosmalen AJ, et al. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow up study. I nt J Radiat Oncol Biol Phys. 2006;64:1081-1091.
51. Borger JH, Hooning MJ, Boersma LJ, et al. Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat Oncol Biol Phys. 2007;69:1131-1138.
52. Taylor CW, McGale P, Povall JM, et al. Estimating cardiac exposure from breast cancer radiotherapy in clinical practice. Int J Radiat Oncol Biol Phys. 2009;73:1061-1068.
53. Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6:557-565.
54. McDonald MW, Godette KD, Whitaker DJ, et al. Three-year outcomes of breast intensity modulated radiation therapy with simultaneous integrated boost. Int J Radiat Oncol Biol Phys. In press.
55. Wai ES, Wells D, Bendorffe B, et al. Phase II study of deep inspiration breath holding (DIBH) and intensity modulated radiation therapy (IMRT) treatment for women with left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:S90. Abstract 200.
56. Whelan TJ, Pignol J, Julian J, et al. Long-term results of a randomized trial of accelerated hypofractionated whole breast irradiation following breast conserving surgery in women with node-negative breast cancer. Int J Radiat Oncol Biol Phys. 2008;72:S28. Abstract 60.
57. Bentzen SM, Agrawal RK, Aird EG, et al. START Trialist Group. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9:331-341.
58. Bentzen SM, Agrawal RK, Aird EG, et al. START Trialist's Group. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;371:1098-1107.
59. Offersen BV, Overgaard M, Kroman N, et al. Accelerated partial breast irradiation as part of breast conserving therapy of early breast cancer: a systematic review. Radiother Oncol. 2009;90:1-13.
60. Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987-1001.
61. Beitsch PD, Vicini FA, Zannis V, et al. Recurrence and survival in the American Society of Breast Surgeons (ASBS) MammoSite RTS registry trial. Int J Radiat Oncol Biol Phys. 2008;72(suppl 1):S2-S3. Abstract 5.
62. Vicini FA, Beitsch P, Quiet C, et al. Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial in patients treated with accelerated partial breast irradiation (APBI). Int J Radiat Oncol Biol Phys. 2009;75(suppl 3):S75. Abstract 159.
63. McHaffie DR, Patel RR, Adkinson JB, et al. Outcome following accelerated partial breast irradiation in patients with ASTRO Consensus Statement cautionary features. Int J Radiat Oncol Biol Phys. 2009;75(suppl 3):S76. Abstract 160.
64. Taghian AG, El-Din MA, Smith BL, et al. Interim results of a phase I/II trial of 3D conformal external beam accelerated partial breast irradiation in patients with early breast cancer. Int J Radiat Oncol Biol Phys. 2008;72(suppl 1): S4. Abstract 8.
65. Chen PY, Vicini FA, Wallace M, et al. Comparative analysis of the efficacy of three forms of accelerated partial breast irradiation from a single institution. Int J Radiat Oncol Biol Phys. 2009;75:S183. Abstract 2006.
66. Hepel JT, Tokita M, MacAusland SG, et al. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009;75:1290-1296.
67. Recht A, Ancukiewicz M, Lu X, et al. Lung-dose volume parameters and the risk of pneumonitis for patients treated with accelerated partial breast irradiation (APBI) using 3D conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2008;72(suppl 1):S4. Abstract 9.
68. Jagsi R, Ben-David M, Moran J, et al. Adverse cosmesis in a protocol investigating IMRT with active breathing control for accelerated partial breast irradiation (APBI). Int J Radiat Oncol Biol Phys. 2008;72(suppl 1):S153. Abstract 1088.
69. Suh WW, Pierce LJ, Vicini FA, et al. A cost comparison analysis of partial versus whole-breast irradiation after breast conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005;62:790-796.
70. Sher DJ, Wittenberg E, Suh WW, et al. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2009;74:440-446.
71. Prosnitz LR, Marks LB. Partial breast irradiation: a cautionary note. Int J Radiat Oncol Biol Phys. 2006;65:319-321.
72. MacDonald SM, Taghian AG. Partial-breast irradiation: toward a replacement for whole-breast irradiation. Expert Rev Anticancer Ther. 2007;7:123-134.
73. Kroman N, Jensen MB, Wohlfahrt J, et al. Factors influencing the effect of age on prognosis in breast cancer: population based study. Br Med J. 2000;320:474-479.
74. Van der Leest M, Evers L, van der Sangen MJ, et al. The safety of breast conserving surgery in breast cancer patients of 40 years and younger. Cancer. 2007;109:1957-1964.
75. Meric F, Mirza NQ, Vlastos G, et al. Positive surgical margins and ipsilateral breast cancer recurrence predict disease-specific survival after breast-conserving therapy. Cancer. 2003;97:926-933.
76. Neuschatz AC, DiPetrillo T, Safaii H, et al. Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breastconserving therapy. Cancer. 2003;97:30-39.
77. Jagsi R, Griffith KA, Koelling T, et al. Rate of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early breast cancer. Cancer. 2007;109:650-657. (Pubitemid 46233225)
78. Deutsch M, Land SR, Begovic M, et al. The incidence of lung carcinoma after surgery for breast carcinoma with and without postoperative radiotherapy. Cancer. 2003;98:1362-1368.
79. Kirova YM, Fournier-Bidoz N, Servoir V, et al. Risk of second malignancy after adjuvant radiotherapy for breast cancer: a large-scale single-institution review. Int J Radiat Oncol Biol Phys. 2007;68:359-363.
80. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1-7.